Syapse, a precision medicine software company, has completed the first close of a $25 million Series C funding round. Ascension Ventures, a subsidiary of St. Louis-based Ascension, the largest Catholic nonprofit health system in the nation, led the financing round.
Existing investors Social Capital Partnership and Safeguard Scientifics also participated in this funding round.
Syapse has carved out a market-leading position in the clinical implementation of precision medicine for oncology and will use this funding round to drive the expansion of its software, the Syapse Precision Medicine Platform, in community health systems. The cloud-based software was built to enable four key processes:
- Integrating clinical, genomic and other molecular data from medical records, labs and pharmacies to see the full longitudinal profile of a patient
- Providing guidance on the appropriate diagnostic and therapeutic strategy, based on clinical best practices
- Implementing treatment decisions more effectively, and coordinating complex care across large, geographically dispersed care teams
- Rigorously measuring patient outcomes to rapidly learn what works and improve best practices